JPWO2020173935A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020173935A5
JPWO2020173935A5 JP2021549575A JP2021549575A JPWO2020173935A5 JP WO2020173935 A5 JPWO2020173935 A5 JP WO2020173935A5 JP 2021549575 A JP2021549575 A JP 2021549575A JP 2021549575 A JP2021549575 A JP 2021549575A JP WO2020173935 A5 JPWO2020173935 A5 JP WO2020173935A5
Authority
JP
Japan
Prior art keywords
alkyl
group
hydrogen
salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021549575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523201A (ja
JP7426398B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/054897 external-priority patent/WO2020173935A1/en
Publication of JP2022523201A publication Critical patent/JP2022523201A/ja
Publication of JPWO2020173935A5 publication Critical patent/JPWO2020173935A5/ja
Application granted granted Critical
Publication of JP7426398B2 publication Critical patent/JP7426398B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021549575A 2019-02-26 2020-02-25 Ras阻害剤としての新規イソインドリノン置換インドールおよび誘導体 Active JP7426398B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19159299 2019-02-26
EP19159299.7 2019-02-26
PCT/EP2020/054897 WO2020173935A1 (en) 2019-02-26 2020-02-25 New isoindolinone substituted indoles and derivatives as ras inhibitors

Publications (3)

Publication Number Publication Date
JP2022523201A JP2022523201A (ja) 2022-04-21
JPWO2020173935A5 true JPWO2020173935A5 (ru) 2023-03-03
JP7426398B2 JP7426398B2 (ja) 2024-02-01

Family

ID=65598476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549575A Active JP7426398B2 (ja) 2019-02-26 2020-02-25 Ras阻害剤としての新規イソインドリノン置換インドールおよび誘導体

Country Status (5)

Country Link
US (1) US20220144810A1 (ru)
EP (1) EP3931188B1 (ru)
JP (1) JP7426398B2 (ru)
CN (1) CN113474340A (ru)
WO (1) WO2020173935A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021345111A1 (en) 2020-09-15 2023-04-06 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
MX2023011633A (es) 2021-03-31 2023-12-15 Sevenless Therapeutics Ltd Inhibidores de sos1 e inhibidores de ras para su uso en el tratamiento del dolor.
CN115232114B (zh) 2021-04-23 2023-12-19 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202334136A (zh) * 2021-11-03 2023-09-01 美商傳達治療有限公司 PI3Kα抑制劑及其製造與使用方法
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682483A1 (en) * 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
MX364438B (es) 2013-03-15 2019-04-26 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
EP3055290B1 (en) 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
EP3325447A1 (en) 2015-07-22 2018-05-30 Araxes Pharma LLC Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
MA47013A (fr) 2015-10-21 2018-08-29 Otsuka Pharma Co Ltd Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
CN110036010A (zh) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
JP2019534260A (ja) 2016-10-07 2019-11-28 アラクセス ファーマ エルエルシー Rasの阻害剤としての複素環式化合物およびその使用方法
JOP20190154B1 (ar) 2016-12-22 2022-09-15 Amgen Inc بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم
US11136308B2 (en) * 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3573971A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Similar Documents

Publication Publication Date Title
RU2468021C2 (ru) Гетероциклические соединения и их применение
JP2018528261A5 (ru)
JP2005523922A5 (ru)
JP2019529518A5 (ru)
JP2004514663A5 (ru)
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
JP2005524631A5 (ru)
JP2008536807A5 (ru)
JPWO2020173935A5 (ru)
JP2011509309A5 (ru)
JP2020506951A5 (ru)
JPWO2020243415A5 (ru)
JPWO2019195124A5 (ru)
CA2550350A1 (en) 2-(hetero)aryl-substituted tetrahydroquinoline derivatives
JP2004525140A5 (ru)
JP2020530007A5 (ru)
JP2007505044A5 (ru)
JP2006503805A5 (ru)
JP2004523478A5 (ru)
KR101010871B1 (ko) 시아노구아니딘 프로드럭
JPWO2020163823A5 (ru)
KR920016418A (ko) Nmda 길항제
JPWO2020139988A5 (ru)
JP2010535203A5 (ru)
AU2015355965B2 (en) Novel PEG derivative